Skip to content
OpenCapital
Get started

Kiniksa Pharmaceuticals International, plc KNSA Cash ratio

Cash ratio at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
2.8×+2.0×
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
0.5×-0.5×
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
1.9×+0.4×
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
6×+3.7×
MoonLake Immunotherapeutics logo
MoonLake ImmunotherapeuticsMLTX
6.5×-4.9×
BridgeBio Pharma logo
BridgeBio PharmaBBIO
1.1×-2.5×

Other financials

Income statement

See full
Revenue$214.3M+55.5%
Gross profit$193.5M+61.3%
Operating income$29.3M+121%
Net income$22.6M+165%
EPS (diluted)$0.27+145%

Balance sheet

See full
Cash & equivalents$190.0M+20.9%
Total debt$9.0M-9.0%
Total equity$605.7M+32.4%
Total assets$825.3M+37.7%

Cash flow

See full
Operating cash flow$50.2M+125%
CapEx$161.0K+62.6%
Free cash flow$50.0M+125%

Valuation

See full
Market cap$4.58B+128%

Profitability

See full
Gross margin89.3%+3.5pp
Operating margin12.4%+10.2pp
Net margin9.7%+7.6pp
FCF margin21.8%+12.2pp

Returns & leverage

See full
Return on equity13.7%+11.3pp
Debt / equity0×0.0×
Current ratio3.8×+0.1×

Where this comes from

Calculated from Kiniksa Pharmaceuticals International, plc’s reported figures.

cash and equivalents/total current liabilities=1.2×

Based on the most recent quarter.

The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kiniksa Pharmaceuticals International, plc's cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kiniksa Pharmaceuticals International, plc's cash ratio?
Kiniksa Pharmaceuticals International, plc (KNSA) reported cash ratio of 1.2× in Q1 2026.
How has Kiniksa Pharmaceuticals International, plc's cash ratio changed year-over-year?
Kiniksa Pharmaceuticals International, plc's cash ratio decreased by 24.9% year-over-year, from 1.6× to 1.2×.
What is the long-term trend for Kiniksa Pharmaceuticals International, plc's cash ratio?
Over 5 years (2020 to 2025), Kiniksa Pharmaceuticals International, plc's cash ratio has grown at a -19.8% compound annual growth rate (CAGR), from 3.6× to 1.2×.
What does cash ratio mean?
Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.